LA JOLLA, Calif., Feb. 14, 2020 /PRNewswire/ -- Robert C. Green, MD, MPH, a medical geneticist
and physician-scientist who directs the G2P Research
Program in translational genomics and health outcomes in
the Division of Genetics at Brigham and Women's Hospital and
Harvard Medical School, has been named
as Chair of Wamberg Genomic Advisors' Advisory Board.
Wamberg Genomic Advisors is the first company dedicated to
making genomic-based programs and services, not typically covered
by health insurance, available at prices everyone can afford. It
developed Cancer Guardian™, the first program that
gives its members access to personalized cancer guidance, onsite
nurse advocates, a second opinion pathology review, a digital
medical records platform, and advanced genomic testing through the
comprehensive cancer support program. Green will help guide
Wamberg Genomic Advisors in its business structure and further
development of product offerings and programs. Green will
also lead the selection of future Advisory Board members from the
science community.
Green is principal investigator of the MedSeq Project, the first
NIH-funded randomized trial to explore the use of whole genome
sequencing in the clinical practice of medicine and co-leads the
BabySeq Project, the first NIH-funded trial of sequencing in
newborns. The MedSeq and BabySeq Projects apply genome sequencing
both in patients who are affected with hereditary disease and in
those who are healthy, in order to study downstream impact on
health, behavior and health care costs.
Dr. Green also directs the recently established Brigham
Preventive Genomics Clinic, the first academic clinic to offer
comprehensive sequencing and interpretation to healthy adults and
their children. He was the lead author of the published
recommendations from the American College of Medical Genetics and
Genomics for management of incidental findings in clinical
sequencing.
Said Tom Wamberg, CEO of Wamberg
Genomic Advisors, "Our organization is committed to providing
access to the most advanced treatments and science to patients
worldwide. We are thrilled to have Dr. Green to help lead and
advance our efforts. We believe that the addition of Dr.
Green will significantly advance the global democratization of
access to the best navigation, treatments and diagnostics in
treating disease. Our focused target for the immediate future
is cancer."
Dr. Phil Smalley, Chief Medical
Director of Wamberg Genomic Advisors concurs. "We are excited
to work with Dr. Green. His knowledge and credibility in the field
of genetics and translational medicine make us stronger as we
endeavor to improve public health."
About Wamberg Genomic Advisors
Wamberg Genomic Advisors is the first company dedicated to making
genomic-based programs and services, not typically covered by
health insurance, available at prices everyone can afford. Advanced
DNA testing can provide insights to individuals and health care
providers for better-informed decisions about overall health,
patient-care paths, and the quality and longevity of life. Wamberg
Genomic Advisors delivers genomic products and services to
employers and their employees via their trusted benefit brokers,
and to policyholders of life insurance companies through qualified
agents. To discover more about Wamberg Genomic Advisors and the
future of genomics,
visit wamberggenomic.com and cancerguardian.com.
View original
content:http://www.prnewswire.com/news-releases/wamberg-genomic-advisors-forms-advisory-board-301004777.html
SOURCE Wamberg Genomic Advisors